Bo Sun

Interests

No activities entered.

Courses

Scholarly Contributions

Journals/Publications

• Sun, B. (2023). Comprehensive Physicochemical Characterization, In Vitro Membrane Permeation, and In Vitro Human Skin Cell Culture of a Novel TOPK Inhibitor, HI-TOPK-032. . International Journal of Molecular Sciences.
• Sun, B. (2023). Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation.
  . International Journal of Molecular Sciences.
• Sun, B. (2022). Design, Physicochemical Characterization, In Vitro Human Cell Culture, In Vitro Permeation and Stability of an Innovative Resatorvid Topical Formulation for Targeted Skin Drug Delivery. Pharmaceutics.
• Sun, B. (2022). Therapeutic Cancer Vaccines—Antigen Discovery, Adjuvants and Delivery Platforms. Pharmaceutics.
• Sun, B., Hyun, H., Li, L. T., & Wang, A. Z. (2020). Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta pharmacologica Sinica, 41(7), 970-985.
  More info

  Cancer immunotherapy has received extensive attention due to its ability to activate the innate or adaptive immune systems of patients to combat tumors. Despite a few clinical successes, further endeavors are still needed to tackle unresolved issues, including limited response rates, development of resistance, and immune-related toxicities. Accumulating evidence has pinpointed the tumor microenvironment (TME) as one of the major obstacles in cancer immunotherapy due to its detrimental impacts on tumor-infiltrating immune cells. Nanomedicine has been battling with the TME in the past several decades, and the experience obtained could be exploited to improve current paradigms of immunotherapy. Here, we discuss the metabolic features of the TME and its influence on different types of immune cells. The recent progress in nanoenabled cancer immunotherapy has been summarized with a highlight on the modulation of immune cells, tumor stroma, cytokines and enzymes to reverse the immunosuppressive TME.
• Yang, F., Medik, Y., Li, L., Tian, X., Fu, D., Brouwer, K. L., Wagner, K., Sun, B., Sendi, H., Mi, Y., & Wang, A. Z. (2020). Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo. Small (Weinheim an der Bergstrasse, Germany), 16(7), e1906360.
  More info

  Hepatotoxicity is a key concern in the clinical translation of nanotherapeutics because preclinical studies have consistently shown that nanotherapeutics accumulates extensively in the liver. However, clinical-stage nanotherapeutics have not shown increased hepatotoxicity. Factors that can contribute to the hepatotoxicity of nanotherapeutics beyond the intrinsic hepatotoxicity of nanoparticles (NPs) are poorly understood. Because of this knowledge gap, clinical translation efforts have avoided hepatotoxic molecules. By examining the hepatotoxicity of nanoformulations of known hepatotoxic compounds, it is demonstrated that nanotherapeutics are associated with lower hepatotoxicity than their small-molecule counterparts. It is also found that the reduced hepatotoxicity is related to the uptake of nanotherapeutics by macrophages in the liver. These findings can facilitate further development and clinical translation of nanotherapeutics.